Duquesne Family Office’s Teva Pharmaceuticals TEVA Stock Holding History

Duquesne Family Office’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$21.2M	Sell	624,999 -1,752,286	-74%	-$58.4M	0.41%	55
2026 Q1	$71.6M	Sell	2,377,285 -3,497,585	-60%	-$113M	2.12%	14
2025 Q4	$183M	Sell	5,874,870 -10,719,065	-65%	-$264M	4.08%	5
2025 Q3	$335M	Buy	16,593,935 +625,000	+4%	+$11M	8.25%	3
2025 Q2	$268M	Buy	15,968,935 +1,089,185	+7%	+$17.6M	6.57%	2
2025 Q1	$229M	Buy	14,879,750 +5,882,350	+65%	+$105M	7.47%	2
2024 Q4	$198M	Buy	8,997,400 +7,569,450	+530%	+$138M	5.33%	4
2024 Q3	$25.7M	Buy	+1,427,950	New	+$25M	0.87%	25
2015 Q2	–	Sell	-790,500	Closed	-$49.2M	–	43
2015 Q1	$49.2M	Buy	+790,500	New	+$46M	6.26%	6
2014 Q3	–	Sell	-1,241,000	Closed	-$65.1M	–	61
2014 Q2	$65.1M	Hold	1,241,000	–	–	4.64%	6
2014 Q1	$65.6M	Hold	1,241,000	–	–	7.4%	4
2013 Q4	$49.7M	Buy	+1,241,000	New	+$48.9M	3.31%	8

Other funds holding TEVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Duquesne Family Office's TEVA Position: Q2 2026 in Review

Duquesne Family Office reduced its Teva Pharmaceuticals (TEVA) stake by 74% in Q2 2026, selling an estimated $58.4M and leaving 624,999 shares worth $21.2M. The position accounts for 0.41% of the portfolio, ranked #55.

Duquesne Family Office first reported a position in TEVA in Q4 2013 and has held it in 12 quarters since. The position peaked at $335M in Q3 2025. 672 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

Duquesne Family Office held 624,999 shares of Teva Pharmaceuticals worth $21.2M as of Q2 2026.
Duquesne Family Office sold 1,752,286 Teva Pharmaceuticals shares in Q2 2026, an estimated $58.4M.
Teva Pharmaceuticals made up 0.41% of Duquesne Family Office's portfolio in Q2 2026, its #55 holding.
Duquesne Family Office first reported a position in Teva Pharmaceuticals in Q4 2013 and has held it in 12 quarters since.
Duquesne Family Office's Teva Pharmaceuticals position peaked at $335M in Q3 2025.
672 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Duquesne Family Office's 13F filing for Q2 2026, filed 14 Aug 2026.